Policy equipoise and interventional superiority
In: Journal of development effectiveness, Band 16, Heft 3, S. 317-331
ISSN: 1943-9407
11 Ergebnisse
Sortierung:
In: Journal of development effectiveness, Band 16, Heft 3, S. 317-331
ISSN: 1943-9407
In: Philosophy and public affairs, Band 48, Heft 4, S. 319-352
ISSN: 1088-4963
In: The journal of political philosophy, Band 27, Heft 4, S. 422-447
ISSN: 1467-9760
In: Journal of social philosophy, Band 47, Heft 2, S. 211-230
ISSN: 1467-9833
In: Ethics & human research: E&HR : a publication of the Hastings Center, Band 45, Heft 1, S. 15-28
ISSN: 2578-2363
ABSTRACTGovernment agencies and nonprofit organizations have increasingly turned to randomized controlled trials (RCTs) to evaluate public policy interventions. Random assignment is widely understood to be fair when there is equipoise; however, some scholars and practitioners argue that random assignment is also permissible when an intervention is reasonably expected to be superior to other trial arms. For example, some argue that random assignment to such an intervention is fair when the intervention is scarce, for it is sometimes fair to use a lottery to allocate scarce goods. We investigate the permissibility of randomization in public policy RCTs when there is no equipoise, identifying two sets of conditions under which it is fair to allocate access to a superior intervention via random assignment. We also reject oft‐made claims that alternative study designs, including stepped‐wedge designs and uneven randomization, offer fair ways to allocate beneficial interventions.
Introduction: Interest in the therapeutic use of cannabidiol (CBD) has reached a fever-pitch in recent months, as CBD-containing products appear everywhere from online retailers to grocery stores and gas stations. The widespread availability of hemp-derived CBD products is confounding given that CBD is a U.S. Food and Drug Administration (FDA)-approved drug, and thus precluded from being added to food and beverages, or included in dietary supplements. The use by manufacturers of disease-related claims on marketing materials and product labels, along with the federal legalization of hemp in December 2018, has created political pressure on FDA to promulgate regulations. Conclusions: Accurate and informative labeling of hemp and hemp-derived CBD products is an important public health issue. FDA-regulated product labels are considered an essential tool for protecting consumers and enabling informed decision-making. Untruthful or unsubstantiated health-related claims, and unallowed Drug Claims, in marketing materials and on labels of CBD products may create harm by enticing consumers to forgo more evidence-based medical interventions. Furthermore, missing or inaccurate labeling of the amount of CBD, delta-9 tetrahydrocannabinol (THC), and potentially harmful contaminants such as pesticides, naturally-occurring yeast and mold or heavy metals may result in harm and/or lack of efficacy. Manufacturers of these products may reasonably be expected to understand and adhere to FDA regulations for labeling and marketing of food, dietary supplements and drugs, both over-the-counter (OTC) and prescription, even though FDA has interpreted federal law as excluding them from these categories. As manufacturers prepare for forthcoming regulations, a better understanding of the basic framework for FDA labeling and marketing regulations for food, dietary supplements and drugs is warranted.
BASE
In: Social theory and practice: an international and interdisciplinary journal of social philosophy, Band 42, Heft 1, S. 123-154
ISSN: 2154-123X
In: Bioethics, Band 34, Heft 8, S. 771-784
SSRN
In: Ethics & human research: E&HR : a publication of the Hastings Center, Band 44, Heft 5, S. 2-21
ISSN: 2578-2363
ABSTRACTPhase I healthy volunteer trials test the safety and tolerability of investigational pharmaceuticals. In them, participants are exposed to study‐drug risks without the possibility of direct medical benefit and typically must spend days or weeks in a residential research facility. Monetary payments are used to incentivize enrollment and compensate participants for their time. Together, these features of phase I healthy volunteer trials create a research context that differs markedly from most other clinical research, including by enrolling disproportionate numbers of economically disadvantaged people of color as participants. Due to these unique trial features and participation patterns, traditional biomedical research oversight offers inadequate ethical and policy guidance for phase I healthy volunteer research. This article details five ethical criteria crafted to be responsive to the particularities of this type of research: translational science value, fair opportunity and burden sharing, fair compensation for service, experiential welfare, and enhanced voice and recourse.
In: SpringerBriefs in Food, Health, and Nutrition Ser.
Contrary to the common belief that dietary supplements are "unregulated" in the United States, nutrients and other dietary ingredient-containing products have been regulated in this country for a little over a century at least in some capacity, initially through the Pure Food and Drug Act (PFDA) of 1906 and culminating with the many anticipated regulations to be implemented following the recent enactment of the Food Safety Modernization Act of 2010 (FSMA). The goal of this brief is to review and discuss the current statutes and regulations surrounding the ingredients, manufacturing standards, safety, and labeling of dietary supplements for the purpose of protecting consumers. .
In: Air & space power journal, Band 25, Heft 2, S. 41-47